Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium breve MAK40B22B

What does the research say about Bifidobacterium breve MAK40B22B?

2 health outcomes synthesised

Bifidobacterium breve MAK40B22B (also referred to as B-3) has been studied across 2 health outcomes in randomized controlled trials. The strongest area of evidence is improved cognitive function, with moderate evidence strength based on 3 studies in older adults with mild cognitive impairment or memory complaints. Notably, all 3 studies reported beneficial effects, though effect sizes varied, and the exact dose and form were not consistently reported.

Strongest evidence: The probiotic shows moderate-strength evidence for improved cognitive function, with all 3 studies (in older adults with mild cognitive impairment or memory complaints) reporting beneficial effects (two small effect sizes, one large). Effective dose and form were not consistently reported across studies.

Mixed or weaker evidence: Reduced body fat mass has low-strength evidence, with 3 studies in healthy pre-obese adults or those with a tendency for obesity showing consistent moderate beneficial effects—2 of 3 were statistically significant, with effects typically observed at 8–12 weeks. Doses and supplement forms were not reported.

Effective dose patterns: No cross-cutting dose insights are possible, as effective doses were not reported consistently across outcomes.

Population insights: The cognitive benefits were observed specifically in older adults with mild cognitive impairment or memory complaints. Body fat reductions were noted in healthy pre-obese adults or those with a tendency for obesity.

Notable caveats: Both evidence syntheses are based on only 3 studies each, making conclusions preliminary. Clinical literature in both areas is subject to publication bias (null results less likely to be published). Additionally, doses and supplement forms were not consistently reported across studies, limiting generalizability to specific products or intake levels.

Frequently asked

  • What is Bifidobacterium breve MAK40B22B good for according to research?
    Based on preliminary research, Bifidobacterium breve MAK40B22B shows potential benefits for improved cognitive function and reduced body fat mass. Evidence comes from 3 studies each, with all studies reporting beneficial effects for cognitive function (moderate evidence) and consistent moderate effects for body fat reduction (low evidence).
  • What dose of Bifidobacterium breve MAK40B22B is typically used in studies?
    The exact dose and form of Bifidobacterium breve MAK40B22B were not consistently reported across the studies for either cognitive function or body fat mass outcomes. As a result, no specific dose range can be determined from the current evidence.
  • Who benefits most from Bifidobacterium breve MAK40B22B?
    Cognitive benefits have been observed primarily in older adults with mild cognitive impairment or memory complaints. Body fat reductions were noted in healthy pre-obese adults or those with a tendency for obesity. These populations appear most studied and responsive.
  • Are there caveats or limitations in the research on Bifidobacterium breve MAK40B22B?
    Yes, both evidence syntheses are based on only 3 studies each, making conclusions preliminary. Clinical literature is subject to publication bias where null-result studies are less likely to be published. Additionally, doses and supplement forms were not consistently reported, limiting generalizability.
  • Does Bifidobacterium breve MAK40B22B help with body fat reduction?
    Research shows that Bifidobacterium breve MAK40B22B consistently demonstrated moderate beneficial effects on reducing body fat mass across 3 studies, with 2 of 3 reporting statistically significant results. Effects were typically observed at 8–12 weeks in adults with pre-obesity or a tendency for obesity, but evidence strength is low due to the small number of studies.

Most-studied combinations with Bifidobacterium breve MAK40B22B

most supplement research is combination research
Also studied with:Bifidobacterium breve VPro 52 (10)
Back to top